2. Search Result
Search Result
Results for "

inactive control

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Biochemical Assay Reagents

13

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121954
    Necrostatin-1 (inactive control)

    Nec-1 (inactive control)

    		 Others Cancer
    Necrostatin-1 (Nec-1) (inactive control) is an inactive analog of Necrostatin-1 (HY-15760). Necrostatin-1 is a potent necroptosis inhibitor .
    Necrostatin-1 (<em>inactive</em> <em>control</em>)
  • HY-136453A
    CR-1-30-B

    		Others Cancer
    CR-1-30-B is an inactive enantiomer of CR-1-31-B. CR-1-30-B, as a control, is inactive against eIF4A and has no apparent effect on the induction of MUC1-C translation .
    CR-1-30-B
  • HY-15517B
    KN-92 hydrochloride
    5 Publications Verification

    		 Others Cancer
    KN-92 hydrochloride is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 hydrochloride is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 .
    KN-92 hydrochloride
  • HY-113894
    Retreversine

    		Aurora Kinase Cancer
    Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .
    Retreversine
  • HY-145081
    Pitnot-2

    		Others Infection
    Pitnot-2 is an inactive analog of clathrin inhibitor Pitstop 2. Pitnot-2 can be used as negative control .
    Pitnot-2
  • HY-118421
    Nullscript

    		Parasite HDAC Infection
    Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM .
    Nullscript
  • HY-15517
    KN-92

    		Others Cancer
    KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92
  • HY-15517A
    KN-92 phosphate
    5 Publications Verification

    		 Others Cancer
    KN-92 phosphate is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 phosphate is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92 phosphate
  • HY-16994
    OICR-0547

    		WDR5 Cancer
    OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .
    OICR-0547
  • HY-119857
    AGK7

    SIRT2 Inhibitor,inactive control

    		 Sirtuin Neurological Disease
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
    AGK7
  • HY-153734
    Inactive ASO (in vivo) sodium

    		Others Others
    Inactive ASO (in vivo) sodium is an inactive Antisense Oligonucleotide. ASO is a class of oligonucleotide molecules, usually composed of 20-30 bases, used to interfere with or regulate gene expression. Inactive ASO (in vivo) sodium is not targeted in the rodent genome and can be used as a negative control for Tofersen. Inactive ASO (in vivo) sodium contains thiophosphate skeleton modification and MOE modification. Cytosine in Inactive ASO (in vivo) is 5' methylcytosine. See References for the location of chemical modifications
    Inactive ASO (in vivo) sodium
  • HY-126300A
    SGC6870N

    		Histone Methyltransferase Cancer
    SGC6870N is inactive against PRMT6 and can be utilized as a negative control. SGC6870N is an inactive enantiomer of SGC6870 (HY-126300) .
    SGC6870N
  • HY-148745
    JG-258

    		HSP Cancer
    JG-258 is an inactive negative control for Hsp70 inhibitors .
    JG-258
  • HY-120343
    GSK106

    		Protein Arginine Deiminase Cardiovascular Disease Inflammation/Immunology Cancer
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 .
    GSK106
  • HY-106029
    4α-TPA

    α-TPA

    		 Others Cancer
    4α-TPA is an inactive form of TPA, and is used as a negative control for TPA-activated events .
    4α-TPA
  • HY-121733
    PHGDH-inactive

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503 .
    PHGDH-inactive
  • HY-154843
    C-Gem

    		Others Cancer
    C-Gem is a control molecule of S-Gem (HY-154842). C-Gem is completely inactive under experimental conditions .
    C-Gem
  • HY-107477
    GSK8573

    		Epigenetic Reader Domain Cancer
    GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .
    GSK8573
  • HY-153887
    HyT36(-Cl)

    		Others Others
    HyT36(-Cl) is the inactive control compound of HyT36, a small molecule hydrophobic tag compound that can be used in protein folding research .
    HyT36(-Cl)
  • HY-13851
    PS47

    		PDK-1 Others
    PS47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1. PS47 can be used as a negative control for PS48 .
    PS47
  • HY-135843
    TH-263

    		Others Cancer
    TH-263, a diaryl sulfonamide derivative, is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257 .
    TH-263
  • HY-145056
    ART615

    		Others Cancer
    ART615 is the related isomer of ART558. ART615, the inactive of ART558, elicits <10% Polθ inhibition at 12 µM, thus serving as a control for ART558 (IC50=7.9 nM) .
    ART615
  • HY-108437
    exo-IWR-1

    		Wnt Infection Cancer
    exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway .
    exo-IWR-1
  • HY-125143
    ABC34

    		MAGL Metabolic Disease
    ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both ABHD6 and PPT122 .
    ABC34
  • HY-115682
    (S)-ZINC-3573

    		Mas-related G-protein-coupled Receptor (MRGPR) Others
    (S)-ZINC-3573 is an inactive enantiomer of ZINC-3573. (R)-ZINC-3573 is a selective MRGPRX2 agonist. (S)-ZINC-3573 and (R)-ZINC3573 are effective and internally controlled probe-pairs for investigating the biology of primate-exclusive receptor .
    (S)-ZINC-3573
  • HY-P3882
    Fmoc-Ala-Glu-Gln-Lys-NH2

    		Amino Acid Derivatives Neurological Disease
    Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein .
    Fmoc-Ala-Glu-Gln-Lys-NH2
  • HY-111457
    BAY-677

    		Others Inflammation/Immunology
    BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
    BAY-677
  • HY-116429A
    7(S)-Maresin 1

    		Reactive Oxygen Species Inflammation/Immunology
    7(S)-Maresin 1 is an inactive 7(S) exomer of Maresin 1, containing a 7(R) hydroxyl group. It can be used as a negative control. Maresin 1 is a specific regulator of endogenous DHA production in the human body, which can stimulate the production and secretion of intracellular Ca 2+ .
    7(S)-Maresin 1
  • HY-108630
    U-73343
    3 Publications Verification

    		 Phospholipase Others
    U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 µM for PLC .
    U-73343
  • HY-135416
    Streptolysin O

    		Endogenous Metabolite Infection
    Streptolysin O, a group A streptococcal toxin, is a well-characterized oxygen-labile prototype of a cholesterol-binding bacterial exotoxin. Streptolysin O causes both lysis of cells and cardiotoxicity. Streptolysin O is widely used for the controlled permeabilization of cell membranes. Streptolysin O exists in two forms, a reduced active state and an oxidized reversibly inactive state .
    Streptolysin O
  • HY-78931A
    (R,S,S,R,S)-Boc-Dap-NE

    		Others Cancer
    (R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,S,R,S)-Boc-Dap-NE
  • HY-78931B
    (S,S,S,S,R)-Boc-Dap-NE

    		Others Cancer
    (S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (S,S,S,S,R)-Boc-Dap-NE
  • HY-145082
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium

    		Others Others
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium is an inactive 1,8-Naphthalimide derivative. 4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium can be used as a negative control for the clathrin inhibitor 3-Sulfo-N-benzyl-1,8-naphthalimide, potassium salt .
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium
  • HY-P5395
    TAT-GluR23A Fusion Peptide

    		HIV Others
    TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)
    TAT-GluR23A Fusion Peptide
  • HY-135416A
    Streptolysin O (≥1000000 units/mg)

    		Endogenous Metabolite Infection
    Streptolysin O (≥1000000 units/mg) is a ≥1000000 units/mg Streptolysin O (HY-135416). Streptolysin O, a group A streptococcal toxin, is a well-characterized oxygen-labile prototype of a cholesterol-binding bacterial exotoxin. Streptolysin O causes both lysis of cells and cardiotoxicity. Streptolysin O is widely used for the controlled permeabilization of cell membranes. Streptolysin O exists in two forms, a reduced active state and an oxidized reversibly inactive state .
    Streptolysin O (≥1000000 units/mg)
  • HY-112306
    Ripretinib

    DCC-2618

    		 c-Kit PDGFR FLT3 VEGFR Apoptosis Cancer
    Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
    Ripretinib
  • HY-P2307A
    Tat-NR2Baa TFA

    		iGluR NO Synthase Neurological Disease
    Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
    Tat-NR2Baa TFA
  • HY-P2307
    Tat-NR2Baa

    		iGluR NO Synthase Neurological Disease
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
    Tat-NR2Baa
  • HY-W011426
    Isopropyl palmitate

    Propan-2-yl hexadecanoate

    		 Biochemical Assay Reagents Liposome Others
    Isopropyl palmitate is an fatty acid ester. Isopropyl palmitate can be used for design and characterization of bioactive bilayer films. The bilayer membrane not only has the ability to scavenge free radicals and inhibit lipid peroxidation, but also can inhibit the growth of known foodborne pathogens. Isopropyl palmitate can be used as an excipient, such as lubricant, oily carrier, solvent, controlled-release transdermal film. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Isopropyl palmitate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: